Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease.
Patients with inflammatory bowel disease (IBD) are at increased risk of invasive pneumococcal infections. Therefore, vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) two months later - is recommended. However, the level of immunogenicity induced by this vaccination schedule in IBD patients with and without immunosuppressive medication remains unclear. We prospectively assessed the immunogenicity of PCV13 followed by PPSV23 in IBD patients by measuring serotype specific pneumococcal IgG antibody concentrations at baseline and 4-8 weeks post-vaccination. Response to vaccination was defined as a post-vaccination antibody concentration ≥1.3mcg/mL for 70% of the measured serotypes. We analyzed the immunogenic effect of four different medication regimens: 1) conventional immunomodulators (i.e. oral prednisolone >10mg/d, thiopurines, methotrexate); 2) anti-Tumor Necrosis Factor agents; 3) combination therapy and 4) no treatment with immunosuppressive agents (control group). 141 IBD patients were included, of whom 37 were controls. Adequate response to vaccination was 59% (61/104) in patients using immunosuppressive agents (group 1, 2, 3) versus 81% (30/37) in controls (OR 0.33 95% CI 0.13-0.82). A combination of different immunosuppressive drugs most severely impaired the immune response to pneumococcal vaccination (response 52%, 15/29). Although the sequential vaccination schedule of PCV13 followed by PPSV23 is safe, immunogenic and hence beneficial in the majority of IBD patients, those receiving immunosuppressive agents and especially those receiving combination therapy, have an impaired immune response compared to controls. Therefore, preferably, vaccinations should be administered before starting immunosuppressive therapy.